MedX Health Corp. MDXHF

MedX Health launches SkinSecure™ to enable direct, non-invasive, objective biological measurements for skin health research. SkinSecure launch is a major product introduction positioned to significantly alter MedX Health trajectory and investor sentiment.

MedX Health Corp. announced the initial closing of a $2,700,000 non-brokered private placement of Series IV Convertible Loan Notes. Raising $2.7 million through convertible notes provides significant capital infusion critical for a microcap health tech firm's operations and strategic advancement.

MedX Health Corp. announced a non-brokered private placement of Series IV Convertible Loan Notes, aiming to raise up to $1.5 million. The offering is intended to provide the company with additional capital to support its growth initiatives and operational needs. The notes will be convertible into common shares at a predetermined price, and the placement is expected to close on or about November 15, 2023. The private placement is expected to provide necessary capital for growth, impacting financial performance moderately.

MedX Health Corp. reported significant advancements in its telemedicine and dermatology services in 2025, highlighting increased adoption of its technology and a growing customer base. The company launched new products aimed at enhancing patient care and improving diagnostic accuracy. Financial performance showed promising growth, with revenue increases attributed to strategic partnerships and expanded market reach. Regulatory approvals for new technologies further positioned MedX Health as a leader in the healthcare sector, setting the stage for future innovations and market expansion. Significant advancements in technology and regulatory approvals are likely to enhance market positioning and investor sentiment.

MedX Health Corp. has successfully completed the final closing of its non-brokered private placement, raising a total of $1.5 million. The funds will be used to support the company's growth initiatives and operational activities. The placement involved the issuance of units at a price of $0.10 per unit, with each unit consisting of one common share and one warrant. The warrants are exercisable at a price of $0.15 for a period of two years. The completion of this financing is expected to enhance MedX's financial position and facilitate its strategic objectives. The completion of the private placement provides necessary funding that may support growth initiatives and operational activities.

MedX Health Corp. has successfully raised $528,000 in the initial closing of a private placement, which is part of a larger effort to secure $2.5 million. The funds will be utilized to support the company's growth initiatives and enhance its product offerings. The capital raised may moderately influence MedX Health's financial performance and growth strategy.

MedX Health Corp. announced the initial closing of a non-brokered private placement, aiming to raise up to $1.5 million. The company plans to extend the offering to accommodate additional investors. The funds will be used for general corporate purposes and to support the company's growth initiatives. The private placement may provide necessary funding for growth initiatives, impacting financial performance moderately.

MedX Health Corp. has appointed Dr. Symon Cotton as a Strategic Advisor focusing on AI and product development. Dr. Cotton brings extensive experience in healthcare technology and innovation, which is expected to enhance MedX's capabilities in artificial intelligence and product offerings. This strategic move aims to strengthen the company's position in the market and drive future growth. The appointment of a seasoned expert in AI and product development is likely to significantly impact MedX's strategic direction and market competitiveness.

MedX Health Corp. has extended a private placement of $2.5 million to support its operations and growth initiatives. Additionally, Paul Matts has been appointed as a strategic advisor to the company, bringing valuable expertise to its leadership team. The private placement and strategic advisory appointment may enhance operational capabilities and market positioning.

MedX Health Corp. has appointed Dr. Paul Matts, a global leader in skin science, as a strategic advisor. Dr. Matts brings extensive experience in dermatology and skin health, which is expected to enhance MedX's capabilities in skin assessment and telemedicine. His expertise will support the company's mission to improve skin health outcomes through innovative technology and services. The appointment of a renowned expert like Dr. Matts is likely to significantly enhance MedX's strategic direction and market positioning in the skin health sector.

MedX Health Corp. has announced a proposed extension of its non-brokered private placement, allowing the company to raise additional funds. The extension aims to provide more time for investors to participate in the offering, which is crucial for supporting the company's growth initiatives and operational needs. The extension of the private placement may provide necessary funding, impacting financial performance and operational capabilities.

MedX Health Corp. has appointed Meghan Geary as the new Senior Vice President of Operations. Geary brings extensive experience in operational leadership and strategic development, which the company believes will enhance its operational efficiency and growth. Her role will focus on optimizing processes and driving the company's operational strategies forward. The appointment of a new Senior Vice President of Operations may moderately influence the company's operational efficiency and strategic direction.

MedX Health Corp. (MDXHF) has announced a proposed non-brokered private placement aimed at raising up to $2,500,000. The company also plans to grant stock options as part of this initiative, which is expected to enhance its financial position and support future growth. The proposed private placement could provide necessary funding for operations and growth, impacting financial performance moderately.

MedX Health Corp. has appointed John Gevisser as Chief Executive Officer, effective immediately. Gevisser previously served as Chief Digital Officer at Health Partners Group and has experience in expanding digital health solutions. His focus will be on international expansion, commercialization of MedX’s technology, and revenue growth. Stephen Lockyer will continue as President. MedX specializes in teledermatology and non-invasive skin assessments, with its SIAscopy® technology enabling accurate imaging for rapid dermatologist review. The appointment of a CEO with extensive experience in digital health and international growth strategies is likely to significantly impact MedX's future performance and market positioning.

MedX Health Corp. has engaged a market maker consultant to enhance liquidity and facilitate trading of its shares. This strategic move aims to improve market visibility and investor engagement, potentially leading to increased trading volume and shareholder interest. The company is focused on expanding its market presence and ensuring a more stable trading environment for its stock. Engaging a market maker consultant may moderately influence trading volume and investor sentiment, but it is not expected to fundamentally alter the company's trajectory.

MedX Health Corp. has completed the final closing of its Non-Brokered Private Placement, raising a total of $2,063,500 by issuing 29,478,571 Units at $0.07 each. The final closing included 8,678,571 Units, with proceeds directed towards the development of the SIAscopy® on DermSecure® telemedicine platform and other corporate purposes. Insiders participated in the placement, and qualified agents received commissions and warrants. The securities issued are subject to a four-month hold period. The funding raised will support product development and market expansion, which could moderately influence the company's financial performance.

MedX Health Corp. has completed a further closing of its non-brokered private placement, raising $511,000 by issuing 7,300,000 units, bringing the total raised to $1,456,000. The company plans to issue up to 35,714,858 units at $0.07 each, aiming for a maximum of $2,500,000. Funds will support the development of its SIAscopy® on DermSecure® telemedicine platform and other corporate purposes. Securities issued are subject to a four-month hold period, and certain insiders may participate in future closings. Qualified agents will receive an 8% commission on gross proceeds and agent's warrants. MedX specializes in skin health technology, with products cleared for use in multiple countries. The funding raised will support product development and market expansion, which could moderately influence the company's financial performance.

MedX Health Corp. has partnered with Vitamed Biomedical and Medispa to expand teledermatology services in Italy. The collaboration will deploy MedX’s SIAscope on DermSecure® platform across Medispa’s network of pharmacies and wellness facilities, enhancing patient access to skin screening and preventive care. This initiative aims to improve early detection of melanoma through non-invasive teledermatology, with the system cleared for clinical use in multiple jurisdictions. The partnership aligns with Medispa’s vision of innovating healthcare delivery and addresses the growing demand for accessible dermatological services in Italy. The partnership significantly enhances MedX's market presence in Italy, a key growth area for teledermatology services.

MedX Health Corp. has entered into a commercial agreement with Health Partners following a successful pilot program in the UK. This partnership aims to enhance the distribution of MedX's telemedicine solutions, particularly in dermatology, and is expected to expand their market presence and improve patient access to healthcare services. The commercial agreement represents a significant strategic move that could enhance market presence and investor sentiment.

MedX Health Corp. announced an extension of its non-brokered private placement to June 6, 2025, allowing for further closings after an initial closing on April 3, 2025, which raised $945,000 from 13,500,000 units. The company plans to raise an additional $1,555,000 by issuing up to 22,214,285 units at $0.07 each. Funds will support the development of the SIAscopy® on DermSecure® telemedicine platform and other corporate purposes. Insiders may participate in the placement, limited to 25% of total funds raised. The extension of the private placement and potential additional funding may moderately influence MedX's financial performance and product development.

MedX Health Corp. has completed the Initial Closing of a Non-brokered Private Placement, raising $945,000 through the issuance of 13,500,000 Units. The company plans to issue up to 35,714,858 Units at $0.07 each, aiming to raise a total of $2,500,000. Funds will support the development of the SIAscopy® on DermSecure® telemedicine platform and other corporate purposes. Securities issued are subject to a four-month hold period. Qualified agents will receive an 8% cash commission and Agent’s Warrants for their services. Insiders may participate in future closings, capped at 25% of total funds raised. The funding will support product development and market expansion, which could moderately influence financial performance.

MedX Health Corp. (MDXHF) has announced a proposed non-brokered private placement aimed at raising up to $2,500,000. Additionally, the company is granting stock options as part of this initiative. The move is intended to bolster its financial position and support ongoing operations. The private placement and stock option grants are expected to provide moderate financial support but may not significantly alter the company's overall trajectory.

MedX Health Corp. announces final closing of non-brokered private placement offering, raising $550,000 from accredited investors for working capital and software development. The private placement offering and extension of loan notes may moderately influence the company's financial performance and strategic development.

MedX Health Corp. completes Initial Closing of Private Placement, extends offering deadline, and updates on Series I Convertible Loan Notes Amendment. The completion of the Private Placement and extension of offering deadline may moderately influence the company's financial performance and market sentiment.

MedX Health First Quarter 2024 Earnings: CA$0.004 loss per share (vs CA$0.007 loss in 1Q 2023). Moderately noticeable influence expected on financial performance and market sentiment.

MedX Health Corp. extends non-brokered Private Placement offering by up to 30 days for up to $2 million. The extension of the Private Placement offering may moderately influence the company's financial performance and investor sentiment.

MedX Health Corp. plans to raise up to $2 million through a private placement and extends the maturity date of Series I Convertible Notes. The proposed private placement and extension of convertible notes maturity date may moderately influence the company's financial performance and operations.

MedX Health Corp. and Health Partners successfully complete pilot project in the UK for skin cancer screening. Partnership with Health Partners and successful pilot project likely to have a significant impact on MedX Health Corp.'s future and market performance.

MedX Health Corp. appoints Dr. Paul Cohen as Medical Spokesperson. Dr. Cohen's appointment as Medical Spokesperson is expected to significantly increase awareness and potentially impact the company's trajectory.

MedX seeks acceptance for amendment to Series I Convertible Loan Notes. Proposed amendment to loan notes may moderately influence financial performance and competitive positioning.